NEW YORK (GenomeWeb News) – SQI Diagnostics said today that it had no revenues for its fiscal fourth quarter.

During the year-ago period, the Canadian microarray-based diagnostics development firm recorded C$5,000 (US$5,077), it said in a regulatory filing.

Net loss for the quarter ended Sept. 30 was C$1.7 million, or C$.04 per share, compared to a loss of C$3.9 million, or C$.11 per share, a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

David Dobbs writes at Buzzfeed that genomics has delivered little on its promises.

In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.

Adam Rutherford discusses genetic genealogy at the Guardian.

Portions of the US 21st Century Cures Act are raising some safety concerns.